Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

In 2013, self-harm cost hospitals in England an estimated £128.6m according to a new study led by the Nuffield Department of Population Health (NDPH) and the Centre for Suicide Research (Department of Psychiatry).

The paper, published in Epidemiology and Psychiatric Sciences, provides the first detailed study of self-harm and associated hospital costs. The authors found that the number of people visiting hospital for self-harm injuries is 60% higher than previously estimated by Public Health England. 

Senior author, Professor Keith Hawton, Director of the Centre for Suicide Research said ‘Suicide affects people of all socioeconomic backgrounds and is the leading cause of death in males aged 10-49 years and females age 10-34 years in England and Wales. Approximately half of individuals who die by suicide have a history of self-harm, and hospital presentation for self-harm often occurs shortly before suicide. This highlights the need for primary and secondary prevention interventions that focus on reducing self-harm presentations and on provision of effective aftercare for those who do self-harm.’ 

The study authors estimated that 228,075 hospital visits in England by 159,857 patients (39% male and 61% female) in 2013 were a result of self-harm. Their definition included intentional self-poisoning and self-injury. They found that 30% of self-harm related hospital visits by men were by those aged between 40 and 49 and that 28% of hospital visits related to self-harm in women were by those aged 19 to 29. The incidence of self-harm was lower in coastal areas, higher inland, and highest in London. 

Read the story on the Nuffield Department of Population Health website

Read the story on the Department of Psychiatry website

Similar stories

Asthma drug budesonide shortens recovery time in non-hospitalised patients with COVID-19

Clinical Trials Coronavirus COVID-19 Research

Inhaled budesonide, a common corticosteroid, is the first widely available, inexpensive drug found to shorten recovery times in COVID-19 patients aged over 50 who are treated at home and in other community settings, reports the PRINCIPLE trial in 1,779 participants.

UK and EU regulators conclude benefits of vaccination continue to outweigh the risks

Coronavirus COVID-19 General

Today, the medical regulators in the UK and Europe have announced their conclusions from their reviews of very rare cases of unusual blood clots in people who have received the Oxford-AstraZeneca coronavirus vaccine.

Link between COVID-19 infection and subsequent mental health and neurological conditions found

Coronavirus COVID-19 General Research

One in three COVID-19 survivors received a neurological or psychiatric diagnosis within six months of infection with the SARS-CoV-2 virus, an observational study of more than 230,000 patient health records published in The Lancet Psychiatry journal estimates. The study looked at 14 neurological and mental health disorders.

New national study of long-term impacts of debilitating lung damage from COVID-19

Coronavirus COVID-19 General Research

A new national study will investigate the long-term effects of lung inflammation and scarring from COVID-19. The study, launched with £2 million of funding from UK Research and Innovation (UKRI), aims to develop treatment strategies and prevent disability.

Opportunities for final goodbyes must be prioritised in COVID-19 pandemic

Coronavirus COVID-19 General Research

Bereaved relatives described the ongoing pain of being absent at the end of a loved-one's life. Many had not seen their relative for weeks or months due to the pandemic. Opportunities must be prioritised for essential connections between families at end-of-life care.